The discovery of rivaroxaban: translating preclinical assessments into clinical practice
Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations of traditional anticoagulants. Rivaroxaban is an oral, direct factor Xa inhibitor that inhibits free and clot-bound...
Saved in:
Main Authors: | Dagmar eKubitza (Author), Elisabeth ePerzborn (Author), Scott D Berkowitz (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2013-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
by: Alexander Solms, et al.
Published: (2019) -
Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
by: Michael Becka, et al.
Published: (2012) -
Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
by: Mariamena Arbitrio, et al.
Published: (2021) -
[Translated article] Excellent Long-term Clinical Response to Rivaroxaban in Livedoid Vasculopathy: A Retrospective Study
by: D. Morgado-Carrasco, et al.
Published: (2023) -
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
by: Stefan Willmann, et al.
Published: (2021)